We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Case-Control Comparison With Intravenous Rituximab.
- Authors
Rotkopf, Hugo; Lévy, Michaël; Copie-Bergman, Christiane; Dupuis, Jehan; Verlinde-Carvalho, Muriel; Itti, Emmanuel; Gagniere, Charlotte; Belhadj, Karim; Tannoury, Jenny; Le Bras, Fabien; Sobhani, Iradj; Haioun, Corinne; Amiot, Aurelien
- Abstract
<bold>Introduction: </bold>Rituximab is a standard treatment for gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML). We sought to compare the effectiveness and safety of subcutaneous and intravenous rituximab in a retrospective case-control study.<bold>Patients and Methods: </bold>All consecutive patients with GML treated with subcutaneous rituximab between January 2017 and December 2018 were included and compared to 3 matched control patients (based on Ann Arbor classification, presence of t(11;18) translocation, history of treatment, and type of current treatment) treated with intravenous rituximab between January 2000 and December 2018. Patients with t(11;18) translocation were treated with rituximab in combination with chlorambucil; the other patients were treated with rituximab alone. Effectiveness was assessed at week 52, and safety was assessed through weeks 0 to 52 and compared by the chi-square test.<bold>Results: </bold>Twenty-five patients were included in the subcutaneous rituximab group and 75 in the intravenous group. There was no difference between the groups in complete remission (78% vs. 76%, P = .99) or overall response rates (91% vs. 89%, P = .99) at week 52. Safety profiles were similar in both groups, with a significant decrease in postinduction grade 2 injection-related reactions and outpatient hospital length of stay in the subcutaneous rituximab group.<bold>Conclusion: </bold>In a small case-control study, we did not find any difference in the effectiveness or safety profiles between subcutaneously and intravenously delivered rituximab for the treatment of patients with GML. We found a decrease in postinduction grade 2 injection-related reactions and outpatient hospital length of stay in the subcutaneous rituximab group.
- Subjects
INTRAVENOUS therapy; B cell lymphoma; CASE-control method; RETROSPECTIVE studies; TREATMENT effectiveness; SUBCUTANEOUS injections
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2021, Vol 21, Issue 1, pe32
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2020.08.014